trending Market Intelligence /marketintelligence/en/news-insights/trending/tayfs18Uw-ijQgeQ2I9W5w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Report: After Johnson & Johnson, Sanofi in talks to acquire Actelion

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Report: After Johnson & Johnson, Sanofi in talks to acquire Actelion

Sanofi SA is in talks to acquire Actelion Pharmaceuticals Ltd. in a deal valued at up to $30 billion, The Wall Street Journal reported Dec. 13, citing sources.

The news follows Johnson & Johnson's decision to abandon a potential takeover of Actelion, which was asking for more than the U.S. pharma giant was willing to pay.

Johnson & Johnson's initial offer for Actelion was CHF246 per share, valuing the company at $26 billion, which Actelion rejected.

Actelion confirmed it was in talks with another party regarding a possible transaction following the Johnson & Johnson split. Sources say that party is Sanofi.

Sanofi reportedly aims to add Actelion's rare-disease drugs to its aging portfolio, which is losing patent protection.